In the last lecture, we talked about tamoxifen,
and the fact that tamoxifen was a failed contraceptive that
became the gold standard for the treatment and prevention of breast cancer.
Here we're now going to consider the evolution of the use of
non-steroidal antioestrogens into being Selective Estrogen Receptor Modulators.
In lecture two, we're considering the SERM story,
Selective Estrogen Receptor Modulators.
A chemoprevention is not a new concept.
It was Professor Antoine Lacassagne,
who back in 1936 made this statement at
the American Association for Cancer Research: "If one accepts the consideration
of adenocarcinoma of the breast as a consequence of
a special hereditary sensibility to the proliferative actions of oestrone"
(In those days, oestradiol was not known to be the main sex steroid and activity),
"one is led to imagine a therapeutic preventative for
subjects predisposed by their heredity to this cancer."
Lacassagne was talking about animal models, oophorectomy,
preventing breast cancer, but a therapeutic preventative became a potential possibility
with the extensive use of tamoxifen in the clinical community and
preclinical information that set the scene to move forward into clinical testing.